Lymphoplasmacytic lymphoma CT scan: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
|||
| (12 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
In | In [[lymphoplasmacytic lymphoma]], [[CT|CT scan]] [[imaging]] of [[chest]], [[abdomen]], and [[pelvis]] may show [[Evidence|evidences]] of [[lymphadenopathy]] and [[hepatomegaly]]. [[CT]] of the [[lungs]] or [[abdomen]] can also be [[diagnostic]] for [[infection]], which is particularly [[Relevance|relevant]] to [[immunocompromised]] [[patients]]. | ||
==CT scan== | ==CT scan== | ||
*CT scan imaging with IV contrast of chest, abdomen, and pelvis can be done to measure the tumor load.<ref name="ct">{{cite journal |vauthors=Banwait R, O'Regan K, Campigotto F, Harris B, Yarar D, Bagshaw M, Leleu X, Leduc R, Ramaiya N, Weller E, Ghobrial IM |title=The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia |journal=Am. J. Hematol. |volume=86 |issue=7 |pages=567–72 |year=2011 |pmid=21681781 |doi=10.1002/ajh.22044 |url=}}</ref> | *[[CT scan]] [[imaging]] with [[IV]] [[contrast]] of [[chest]], [[abdomen]], and [[pelvis]] can be [[done]] to [[Measurement|measure]] the [[tumor]] load.<ref name="ct">{{cite journal |vauthors=Banwait R, O'Regan K, Campigotto F, Harris B, Yarar D, Bagshaw M, Leleu X, Leduc R, Ramaiya N, Weller E, Ghobrial IM |title=The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia |journal=Am. J. Hematol. |volume=86 |issue=7 |pages=567–72 |year=2011 |pmid=21681781 |doi=10.1002/ajh.22044 |url=}}</ref><ref name="pmid22096219">{{cite journal| author=Saboo SS, Krajewski KM, O'Regan KN, Giardino A, Brown JR, Ramaiya N et al.| title=Spleen in haematological malignancies: spectrum of imaging findings. | journal=Br J Radiol | year= 2012 | volume= 85 | issue= 1009 | pages= 81-92 | pmid=22096219 | doi=10.1259/bjr/31542964 | pmc=3473934 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22096219 }}</ref> | ||
* | *[[Lymphoplasmacytic lymphoma]] shows [[evidence]] of [[lymphadenopathy]], and [[hepatosplenomegaly]].<ref name="ct" /> | ||
*CT of the lungs or abdomen can also be diagnostic for infection, which is particularly relevant to [[immunocompromised]] patients. | *CT of the [[lungs]] or [[abdomen]] can also be [[diagnostic]] for [[infection]], which is particularly [[Relevance|relevant]] to [[immunocompromised]] [[patients]]. | ||
{| | {| | ||
| | | | ||
[[File: | [[File:Ct wm gif.gif|thumb|400px|none|Abdominal [[computed tomography]] ([[Computed tomography|CT]]) showing significant [[hemoperitoneum]], with [[extravasation]] of contrast into the right flank/paracolic gutter. [[Hepatomegaly]] and [[splenomegaly]] are clearly seen. [https://openi.nlm.nih.gov/detailedresult.php?img=PMC2944189_1752-1947-4-300-7&query=waldenstrom+macroglobulinaemia&it=xg&req=4&npos=21 Source: Charakidis M. et al, Department of Haematology-Oncology, Royal Hobart Hospital, Tasmania, 7000, Australia.]]] | ||
| | | | ||
[[File:CT | [[File:CT splenic transaxial slices.png|thumb|500px|none|Transaxial slices representative of the isodose distribution of the 3D-CRT treatment plan delivered for the whole spleen. A, In the first stage, isodose curves were produced by 3 oblique isocentric photon fields of beam quality 10-MV; B, In the second stage, isodose curves were produced by 5 oblique isocentric photon fields of beam quality 10-MV. [https://openi.nlm.nih.gov/detailedresult.php?img=PMC3428667_1748-717X-7-58-2&query=waldenstrom+macroglobulinaemia&it=xg&req=4&npos=56 Source: Wei Z. et al, Department of Radiotherapy, Cancer Centre, Qilu Hospital, Shandong University, 107 Wenhuaxi Street, Jinan, Shandong 250012, China.]]] | ||
| | | | ||
[[File:Ct | |} | ||
|- | {| | ||
| | |||
[[File:Ct before n after tx gif.gif|thumb|300px|none|Response to [[mTOR]]-inhibitor treatment in [[Waldenström's macroglobulinemia|Waldenstrom's macroglobulinemia]] and lung toxicity. Baseline contrast-enhanced coronal [[CT-scans|CT]] images in a 59-year-old woman show [[retroperitoneal]] [[lymphadenopathy]] (black arrows) and mild [[splenomegaly]] (A). Five months after the start of treatment, coronal contrast-enhanced CT shows decreased [[adenopathy]] and splenomegaly (B). At baseline, clear lung bases were present (C). On a five-month follow-up CT (D), new ground-glass and reticular opacities developed in lung bases (white arrows), in keeping with [[mTOR]]-associated pneumonitis. The patient was asymptomatic. mTOR = mammalian target of rapamycin.[https://openi.nlm.nih.gov/detailedresult.php?img=PMC5240491_kjr-18-28-g007&query=waldenstrom+macroglobulinaemia&it=xg&req=4&npos=36 Source: Krajewski KM. et al, Department of Imaging, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Radiology, Brigham and Women's Hospital, Boston, MA 02115, USA]]] | |||
| | |||
[[File:CT bing neel syn gif.gif|thumb|300px|none|(A) Contrast-enhanced axial and coronal T1-weighted images show a well-enhanced mass along the left [[tentorium]] and [[Cavernous sinus|cavernous]] sinus (arrows). This mass also extends into the contralateral [[tentorium]] and falx (arrowheads). (B) A marked decrease in the size of the mass in the [[tentorium]] and falx after [[radiation therapy]] and fludarabine treatment.[https://openi.nlm.nih.gov/detailedresult.php?img=PMC2694623_jkms-22-1079-g001&query=waldenstrom+macroglobulinaemia&it=xg&req=4&npos=28 Source: Kim HD. et al, Department of Internal Medicine, Yeoungnam University College of Medicine, Daegu, Korea.]]] | |||
| | | | ||
[[File: | [[File:Ct splenomegaly gif.gif|thumb|300px|none| Sequential [[computed tomography]] scan images at the same level. A, At the diagnosis of the disease (19/06/2008); B, Relapsed after chlorambucil and thalidomide (25/06/2009); C, Before the first stage of 3D-CRT (12/12/2009); D, Before the second stage of 3D-CRT (22/06/2010); E, At one month after the second stage of 3D-CRT (17/08/2010); F, At one year after the second stage of 3D-CRT (06/07/2011). [https://openi.nlm.nih.gov/detailedresult.php?img=PMC3428667_1748-717X-7-58-1&query=waldenstrom+macroglobulinaemia&it=xg&req=4&npos=55 Source: Wei Z. et al, Department of Radiotherapy, Cancer Centre, Qilu Hospital, Shandong University, 107 Wenhuaxi Street, Jinan, Shandong 250012, China.]]] | ||
| | | | ||
|} | |} | ||
| Line 30: | Line 33: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: | [[Category:Disease]] | ||
[[Category:Blood]] | |||
[[Category:Hematology]] | |||
Latest revision as of 17:13, 29 October 2019
|
Lymphoplasmacytic lymphoma Microchapters |
|
Differentiating Lymphoplasmacytic Lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Lymphoplasmacytic lymphoma CT scan On the Web |
|
American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma CT scan |
|
Risk calculators and risk factors for Lymphoplasmacytic lymphoma CT scan |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
Overview
In lymphoplasmacytic lymphoma, CT scan imaging of chest, abdomen, and pelvis may show evidences of lymphadenopathy and hepatomegaly. CT of the lungs or abdomen can also be diagnostic for infection, which is particularly relevant to immunocompromised patients.
CT scan
- CT scan imaging with IV contrast of chest, abdomen, and pelvis can be done to measure the tumor load.[1][2]
- Lymphoplasmacytic lymphoma shows evidence of lymphadenopathy, and hepatosplenomegaly.[1]
- CT of the lungs or abdomen can also be diagnostic for infection, which is particularly relevant to immunocompromised patients.
 |
 |
 |
 |
 |
References
- ↑ 1.0 1.1 Banwait R, O'Regan K, Campigotto F, Harris B, Yarar D, Bagshaw M, Leleu X, Leduc R, Ramaiya N, Weller E, Ghobrial IM (2011). "The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia". Am. J. Hematol. 86 (7): 567–72. doi:10.1002/ajh.22044. PMID 21681781.
- ↑ Saboo SS, Krajewski KM, O'Regan KN, Giardino A, Brown JR, Ramaiya N; et al. (2012). "Spleen in haematological malignancies: spectrum of imaging findings". Br J Radiol. 85 (1009): 81–92. doi:10.1259/bjr/31542964. PMC 3473934. PMID 22096219.